Clinical characteristics of study participants
| CAVS | CAD | P value | |
| Number of patients | 476 | 414 | |
| Men | 271 (57) | 235 (57) | 0.93 |
| Age, years | 72.0 (8.7) | 71.1 (8.7) | 0.10 |
| Body mass index, kg/m2 | 28.1 (5.2) | 27.5 (4.3) | 0.03 |
| Active smokers | 48 (10) | 48 (12) | 0.43 |
| Coronary artery disease | 244 (51) | 414 (100) | <0.0001 |
| Diabetes | 140 (29) | 126 (30) | 0.75 |
| Hypertension | 339 (71) | 291 (70) | 0.54 |
| Lipid-lowering therapy | 306 (64) | 341 (82) | <0.0001 |
| Total cholesterol, mmol/L | 4.35 (1.07) | 4.06 (0.99) | <0.0001 |
| LDL cholesterol, mmol/L | 2.41 (0.91) | 2.21 (0.80) | 0.0004 |
| HDL cholesterol, mmol/L | 1.26 (0.36) | 1.15 (0.34) | <0.0001 |
| Apolipoprotein B, g/L | 0.71 (0.21) | 0.66 (0.20) | <0.0001 |
| Triglycerides, mmol/L | 1.51 (0.81) | 1.56 (0.77) | 0.30 |
| Creatinine, μmol/L | 96.6 (40.2) | 91.9 (20.1) | 0.02 |
| Lp-PLA2, μmol/min/mL | 0.017 (0.005) | 0.016 (0.005) | <0.0001 |
Data are presented as mean (SD) or n (%).
CAD, coronary artery disease; CAVS, calcific aortic valve stenosis; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Lp-PLA2, lipoprotein-associated phospholipase A2.